Posted inNews and Updates
First Patient Completes Landmark Cancer Clinical Trial
A first patient has completed a breakthrough cancer clinical trial, marking a major milestone in the development of life-saving, targeted therapies.
Posted inNews and Updates
Biological Age vs. Chronological Age: Rethinking Healthcare
New research challenges traditional age-based healthcare, suggesting biological markers are better predictors for preventive care and disease risk.
Posted inNews and Updates
CRO Market Growth: Future Trends and Forecasts to 2034
Discover the future of the global CRO market through 2034. Explore key trends, AI integration, and the growth of clinical trial outsourcing in healthcare.
Posted inNews and Updates
FDA Clears First Human Trial for Novel Oral MS Therapy
The FDA has greenlit the first human trial for a novel oral MS drug, marking a potential shift toward more convenient, targeted neuro-inflammatory care.
Posted inNews and Updates
Breast Cancer Care: How Clinical Trial Data Drives Decisions
Discover how evolving clinical trial data and molecular breakthroughs are shaping modern breast cancer treatment protocols and improving patient outcomes.
Posted inNews and Updates
Natera Partners for Advanced Skin Cancer ctDNA Trial
New study uses Natera’s ctDNA technology to monitor advanced skin cancer patients, aiming to improve treatment accuracy through precision oncology.
Posted inNews and Updates
Protalix BioTherapeutics Q2 2026 Financial Update
Protalix BioTherapeutics reveals its Q2 2026 financial status and progress on its lead rare disease pipeline. Get the latest update on their clinical growth.
Posted inNews and Updates
BD Launches PREVENT Trial for Advanced Tissue Regeneration
BD has launched the PREVENT trial to advance tissue regeneration technology. Discover how this clinical study aims to transform surgical repair outcomes.
Posted inNews and Updates
Arch Biopartners Eyes US Expansion for LSALT Peptide Trial
Arch Biopartners is expanding its LSALT peptide clinical trials into the US to combat organ inflammation. Discover how this therapy targets DPEP-1.
Posted inNews and Updates
Reshaping Oncology Trials: The Daraxonrasib Blueprint
Discover how Daraxonrasib’s revolutionary resistance mapping is setting a new standard for oncology trial design, patient stratification, and survival.